SEC Company Response from enVVeno Medical Corp (NVNO, NVNBW) (CIK 0001661053) (NVNO) — Apr 25, 2019
enVVeno Medical Corp (NVNO, NVNBW) (CIK 0001661053)
Date: April 25, 2019 · CIK: 0001661053 · Accession: 0001493152-19-005917
AI Filing Summary & Sentiment
File numbers found in text: 333-230598
Letter
Hancock Jaffe Laboratories, Inc.
Doppler
Irvine, CA 92618
April 25, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
Re: Hancock Jaffe Laboratories, Inc.
Registration Statement on Form S-1
Filed March 29, 2019
File No. 333-230598
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Hancock Jaffe Laboratories, Inc. (the “Registrant”) hereby requests acceleration of effectiveness of the above referenced Registration Statement on Form S-1 so that it will become effective at 4:30 p.m., Eastern time, on Monday, April 29, 2019, or as soon as thereafter as is practicable.
Very
truly yours,
/s/
Robert A. Berman
Show Raw Text
CORRESP
1
filename1.htm
Hancock
Jaffe Laboratories, Inc.
70
Doppler
Irvine,
CA 92618
April
25, 2019
VIA
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
DC 20549
Re:
Hancock
Jaffe Laboratories, Inc.
Registration
Statement on Form S-1
Filed
March 29, 2019
File
No. 333-230598
Ladies
and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Hancock Jaffe Laboratories, Inc. (the “Registrant”)
hereby requests acceleration of effectiveness of the above referenced Registration Statement on Form S-1 so that it will become
effective at 4:30 p.m., Eastern time, on Monday, April 29, 2019, or as soon as thereafter as is practicable.
Very
truly yours,
/s/
Robert A. Berman
Robert
A. Berman
President
and Chief Executive Officer
cc:
Ellenoff Grossman & Schole LLP